CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1–Infected Children Receiving Highly Active Antiretroviral Therapy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Acquired Immune Deficiency Syndromes

• Publication date

  2010-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/QAI.0b013e3181bf648aPMID 19890215PMCID PMC3119357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

  2008cited by this paper
• Changes are recommended in use of nelfinavir.

  2008cited by this paper
• The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.

  2006cited by this paper
• The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis

  2006cited by this paper
• Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

  2005cited by this paper
• An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

  2005cited by this paper
• Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.

  2005cited by this paper
• CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19

  2004cited by this paper
• MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

  2003cited by this paper
• Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.

  2003cited by this paper
• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

  2002cited by this paper
• Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.

  2002cited by this paper
• Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities

  2001cited by this paper
• Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

  1999cited by this paper
• Transport, metabolism and elimination mechanisms of anti-HIV agents.

  1999cited by this paper
• Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

  1998cited by this paper
• HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

  1998cited by this paper
• Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

  1997cited by this paper
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper

• ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?

  2021cites this paper
• Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety

  2018cites this paper
• 3 Pharmacogenetics and Metabolism : Past , Present and Future

  2017cites this paper
• Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women

  2017cites this paper
• Pharmacogenetic considerations for HIV treatment in different ethnicities: an update

  2017cites this paper
• Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics

  2016cites this paper
• Implications of Pharmacogenetics for Antimicrobial Prescribing

  2016cites this paper
• Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

  2015cites this paper
• Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.

  2015cites this paper
• Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

  2014cites this paper
• Pharmacokinetic targets of antiretroviral therapy in children and adolescents

  2013cites this paper
• P‐glycoprotein (MDR1/ABCB1)

  2013cites this paper
• The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition

  2012cites this paper
• Pharmacogenomic Aspects of Antiretroviral Therapy

  2012cites this paper
• Pharmacogenetics and Metabolism: Past, Present and Future

  2012cites this paper
• Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents

  2011cites this paper
• P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations.

  2011cites this paper
• Optimizing Antiretroviral Therapy in Children and Adolescents with HIV Infection

  2010cites this paper
• Pharmacogenomics and Personalized Medicine Dovepress Role of Cytochrome P450 Genotype in the Steps toward Personalized Drug Therapy

  year unknowncites this paper